Patient Comment on Mobocertinib for Exon 20

Improved Screening Uptake Could Help Double Lung Cancer Survival by 2025

Promising Results for Lurbinectedin in SCLC When Paired with Irinotecan

Deeper Understanding of EGFR Mutation Subgroups Will Further Personalize Treatment for NSCLC

Trastuzumab Deruxtecan Potential New Treatment Options for HER2+ NSCLC

New Nodal Descriptor Classification Potentially Better at Differentiating Patients

Targeting KRAS in Lung Cancer: The Past, Present, and Future 

Envisioning A Tobacco-Free Generation

Nivolumab Boosted Survival in Relapsed Mesothelioma

Sotorasib Shows Early Activity Against KRAS G12C Mutant NSCLC

KEYNOTE-598: Dual PD-1 and CTLA-4 Checkpoint Blockade Confers No Therapeutic Benefit Beyond PD-1 Blockade Alone in PD-L1–Positive NSCLC

LCMC3 Findings Indicate Neoadjuvant Atezolizumab Safe, Efficacious in Resectable Stage IB-IIIB NSCLC